Bonk (NASDAQ:BNKK) Shares Up 2% – Should You Buy?

Shares of Bonk, Inc. (NASDAQ:BNKK) were up 2% on Tuesday . The stock traded as high as $1.07 and last traded at $1.03. 88,291 shares traded hands during trading, a decline of 4% from the average daily volume of 91,549 shares. The stock had previously closed at $1.01.

Wall Street Analyst Weigh In

BNKK has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Bonk from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Bonk in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Bonk Stock Performance

The stock has a market capitalization of $8.48 million, a price-to-earnings ratio of -0.23 and a beta of 1.98. The business has a 50-day moving average of $1.36 and a 200-day moving average of $2.48.

Bonk (NASDAQ:BNKK) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $0.79 million during the quarter. Bonk had a negative net margin of 838.37% and a negative return on equity of 148.62%.

Institutional Investors Weigh In On Bonk

Several hedge funds have recently made changes to their positions in the business. State Street Corp acquired a new position in Bonk in the 4th quarter valued at about $33,000. Steward Partners Investment Advisory LLC acquired a new stake in Bonk during the 4th quarter worth approximately $37,000. Jane Street Group LLC purchased a new position in shares of Bonk in the 4th quarter valued at approximately $96,000. Finally, Geode Capital Management LLC purchased a new position in shares of Bonk in the 4th quarter valued at approximately $128,000. Institutional investors and hedge funds own 12.55% of the company’s stock.

Bonk Company Profile

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.